While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
TipRanks on MSN
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt
InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
Gastroenterology specialists Dr Andy Li and Dr Jessica Gurung outline a rational approach to investigating recurrent ...
InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...
InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa ...
InflaRx (IFRX) outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this ...
No Name Club were among the many groups to pay tribute to Edith Geraghty from Belmullet who passed away following an illness ...
Nearly invisible and deceptively thin, this ice is one of winter’s deadliest hazards. Here’s how it forms and why it causes ...
This sexually transmitted infection is almost entirely preventable. Here's what experts say you really need to know to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback